In diabetes patients at high cardiovascular risk undergoing AF catheter ablation, SGLT2 inhibitor treatment was associated with lower AF recurrences, less cardioversions and repeat ablations,26 which is similar to an analysis on HFrEF patients undergoing cryoballoon ablation with a higher freedom from AF recurrences.27 This evidence concerns the gene SLC5A2 and diabetes mellitus.